Regenxbio Inc 's ability to collect accounts receivable sequentially worsen to 4.13, pointing to a challenging and on top of that deteriorating business climate for the Biotechnology & Pharmaceuticals industry. Regenxbio Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 88 days, from 85 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 430 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2766 to 2908.

What is Receivable Turnover Ratio?
What is Regenxbio Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RGNX Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	430.66 %	-44.82 %	28.85 %	7.38 %	-11.44 %
Y / Y Revenue Change	405.73 %	-92.82 %	43 %	22.88 %	-4.2 %
Receivable Turnover Ratio (TTM)	4.13	4.29	7.57	7.66	7.56
RGNX's Total Ranking	# 2908	# 2766	# 2257	# 1537	# 2347
Accounts Receivable average collection period days	88	85	48	48	48
Seq. Receivable Change	967.83 %	-61.95 %	4.07 %	25.49 %	11.03 %
Seq. Revenue Change	1589.64 %	-78.93 %	2.03 %	39.21 %	-76 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 46
Healthcare Sector	# 431
Overall Market	# 2908

Receivable Turnover Ratio Statistics
High	Average	Low
25.43	8.45	1.68
(Dec 31 2017)		(Jun 30 2020)

RGNX Company Profile • Back to RGNX Efficiency Comparisons • Compare RGNX Receivables Turnover Ratio to its Competitors

Financial Statements
Regenxbio Inc 's Accounts Receivable	$ 107 Millions	Visit RGNX's Balance sheet
Regenxbio Inc 's Sales TTM	$ 174 Millions	Visit RGNX's Income Statement
Sources of RGNX's Revenues		Visit RGNX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RGNX's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RGNX's Growth Rates	RGNX's Roa	RGNX's Inventory Turnover Ratio	RGNX's Dividend Comparisons
RGNX's Profitability Ratios	RGNX's Roi	RGNX's Asset Turnover Ratio	RGNX's Dividend Growth
RGNX's Valuation Ratios	RGNX's Roe	RGNX's Financial Strength Ratios	RGNX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Bellevue Life Sciences Acquisition Corp	4.47	$ 1.809 Millions	$ 0.404 Millions
Vaso Corporation	4.44	$ 80.220 Millions	$ 18.048 Millions
Fulgent Genetics Inc	4.43	$ 322.973 Millions	$ 72.906 Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________	4.40	$ 25.185 Millions	$ 5.729 Millions
Neurocrine Biosciences Inc	4.40	$ 3,373.900 Millions	$ 767.475 Millions
Globus Medical Inc	4.33	$ 3,144.934 Millions	$ 726.626 Millions
Organon and Co	4.31	$ 6,139.000 Millions	$ 1,422.750 Millions
Innoviva Inc	4.31	$ 420.630 Millions	$ 97.520 Millions
Alkermes Plc	4.30	$ 1,667.652 Millions	$ 388.132 Millions
Glaukos Corp	4.29	$ 500.031 Millions	$ 116.471 Millions
Lantheus Holdings Inc	4.24	$ 1,555.343 Millions	$ 367.122 Millions
Dexcom Inc	4.22	$ 4,968.800 Millions	$ 1,176.100 Millions
Supernus Pharmaceuticals inc	4.22	$ 830.438 Millions	$ 196.999 Millions
Vericel Corporation	4.18	$ 306.303 Millions	$ 73.289 Millions
Apyx Medical Corp	4.14	$ 58.105 Millions	$ 14.035 Millions
Regenxbio Inc	4.13	$ 174.482 Millions	$ 42.238 Millions
Inspiremd Inc	4.12	$ 10.502 Millions	$ 2.550 Millions
Amgen Inc	4.07	$ 38,095.000 Millions	$ 9,356.250 Millions
Nexalin Technology Inc	4.07	$ 0.217 Millions	$ 0.053 Millions
Medinotec Inc	4.07	$ 10.247 Millions	$ 2.519 Millions
Outset Medical Inc	4.06	$ 117.551 Millions	$ 28.959 Millions
Butterfly Network Inc	4.05	$ 112.360 Millions	$ 27.732 Millions
Ironwood Pharmaceuticals inc	4.04	$ 389.316 Millions	$ 96.422 Millions
Pelthos Therapeutics Inc	4.03	$ 43.304 Millions	$ 10.757 Millions
Revvity Inc	4.03	$ 2,911.811 Millions	$ 723.421 Millions
Gyre Therapeutics Inc	4.02	$ 119.383 Millions	$ 29.697 Millions
Vaxart Inc	4.02	$ 243.064 Millions	$ 60.514 Millions
Pro dex Inc	4.01	$ 77.548 Millions	$ 19.357 Millions
Xencor Inc	3.99	$ 104.973 Millions	$ 26.335 Millions
Bridgebio Pharma Inc	3.99	$ 713.069 Millions	$ 178.918 Millions

Date modified: 2026-09-03T21:13:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.